Conflict of Interest Policies and Industry Relationships of Guideline Development Group Members: A Cross-Sectional Study of Clinical Practice Guidelines for Depression

TitleConflict of Interest Policies and Industry Relationships of Guideline Development Group Members: A Cross-Sectional Study of Clinical Practice Guidelines for Depression
Publication TypeJournal Article
Year of Publication2017
AuthorsCosgrove, L, Krimsky, S, Wheeler, EE, Peters, SM, Brodt, M, Shaughnessy, AF
JournalAccountability in Research: Policies & Quality Assurance
Volume24
Issue2
Pagination99-115
Date Published2017
Publication Languageeng
ISBN Number08989621
KeywordsANTIDEPRESSANTS , Clinical , Conflict , DEPRESSION , Disclosure , Mental , Pharmaceutical , PUBLIC , research
AbstractBecause of increased attention to the issue of trustworthiness of clinical practice guidelines, it may be that both transparency and management of industry associations of guideline development groups (GDGs) have improved. The purpose of the present study was to assess a) the disclosure requirements of GDGs in a cross-section of guidelines for major depression; and, b) the extent and type of conflicts of panel members. Treatment guidelines for major depression were identified and searched for conflict of interest policies and disclosure statements. Multi-modal screens for undeclared conflicts were also conducted. Fourteen guidelines with a total of 172 panel members were included in the analysis. Eleven of the 14 guidelines (78%) had a stated conflict of interest policy or disclosure statement, although the policies varied widely. Most (57%) of the guidelines were developed by panels that had members with industry financial ties to drug companies that manufacture antidepressant medication. However, only a minority of total panel members (18%) had such conflicts of interest. Drug company speakers bureau participation was the most common type of conflict. Although some progress has been made, organizations that develop guidelines should continue to work toward greater transparency and minimization of financial conflicts of interest. 
NotesCosgrove, Lisa 1; Krimsky, Sheldon 2; Wheeler, Emily E. 1; Peters, Shannon M. 1; Brodt, Madeline 1; Shaughnessy, Allen F. 3,4; Affiliations: 1: Department of Counseling and School Psychology, University of Massachusetts Boston, Boston, Massachusetts, USA; 2: Department of Urban and Environmental Policy and Planning, Tufts University, Medford, Massachusetts, USA; 3: Department of Family Medicine, Tufts University School of Medicine, Boston, Massachusetts, USA; 4: Tufts University Family Medicine Residency at Cambridge Health Alliance, Malden, Massachusetts, USA; Issue Info: 2017, Vol. 24 Issue 2, p99; Thesaurus Term: CONFLICT of interests; Thesaurus Term: PHARMACEUTICAL industry; Subject Term: MENTAL depression -- Treatment; Subject Term: ANTIDEPRESSANTS; Subject Term: RESEARCH bias; Author-Supplied Keyword: clinical practice guidelines; Author-Supplied Keyword: conflict of interest; Author-Supplied Keyword: depression; Author-Supplied Keyword: disclosure policies; Author-Supplied Keyword: public trust; Author-Supplied Keyword: research bias; NAICS/Industry Codes: 325410 Pharmaceutical and medicine manufacturing; NAICS/Industry Codes: 325411 Medicinal and Botanical Manufacturing; NAICS/Industry Codes: 325412 Pharmaceutical Preparation Manufacturing; NAICS/Industry Codes: 414510 Pharmaceuticals and pharmacy supplies merchant wholesalers; NAICS/Industry Codes: 424210 Drugs and Druggists' Sundries Merchant Wholesalers; Number of Pages: 17p; Document Type: Article
DOI10.1080/08989621.2016.1251319

Discipline: 

Subject: 

Publication: